BACKGROUND: Pendimethalin, a widely used herbicide, has been classified as a group C possible human carcinogen by the U.S. Environmental Protection Agency. We evaluated the incidence of cancer in relation to reported pendimethelin use among pesticide applicators in the Agricultural Health Study, a prospective cohort of licensed pesticide applicators in Iowa and North Carolina. METHODS: Information on pesticide use came from two questionnaires (enrollment and take-home). The present analysis includes 9089 pendimethalin-exposed and 15,285 nonpendimethalin-exposed pesticide applicators with complete information on pendimethalin use and covariates from a take-home questionnaire. We conducted Poisson regression analyses to evaluate the association of pendimethalin exposure with cancer incidence (mean follow-up = 7.5 years) using two exposure metrics: tertiles of lifetime days of exposure and tertiles of intensity-weighted lifetime days of exposure. RESULTS: Overall cancer incidence did not increase with increasing lifetime pendimethalin use, and there was no clear evidence of an association between pendimethalin use and risks for specific cancers. The risk for rectal cancer rose with increasing lifetime pendimethalin exposure when using nonexposed as the reference (rate ratio = 4.3; 95% confidence interval = 1.5-12.7 for the highest exposed subjects; P for trend = 0.007), but the association was attenuated when using the low exposed as the referent group (P for trend = 0.08). Similar patterns for rectal cancer were observed when using intensity-weighted exposure-days. The number of rectal cancer cases among the pendimethalin-exposed was small (n = 19). There was some evidence for an elevated risk for lung cancer, but the excess occurred only in the highest exposure category for lifetime pendimethalin exposure. The trends for lung cancer risk were inconsistent for different exposure metrics. CONCLUSIONS: We did not find a clear association of lifetime pendimethalin exposure either with overall cancer incidence or with specific cancer sites.
BACKGROUND:Pendimethalin, a widely used herbicide, has been classified as a group C possible human carcinogen by the U.S. Environmental Protection Agency. We evaluated the incidence of cancer in relation to reported pendimethelin use among pesticide applicators in the Agricultural Health Study, a prospective cohort of licensed pesticide applicators in Iowa and North Carolina. METHODS: Information on pesticide use came from two questionnaires (enrollment and take-home). The present analysis includes 9089 pendimethalin-exposed and 15,285 nonpendimethalin-exposed pesticide applicators with complete information on pendimethalin use and covariates from a take-home questionnaire. We conducted Poisson regression analyses to evaluate the association of pendimethalin exposure with cancer incidence (mean follow-up = 7.5 years) using two exposure metrics: tertiles of lifetime days of exposure and tertiles of intensity-weighted lifetime days of exposure. RESULTS: Overall cancer incidence did not increase with increasing lifetime pendimethalin use, and there was no clear evidence of an association between pendimethalin use and risks for specific cancers. The risk for rectal cancer rose with increasing lifetime pendimethalin exposure when using nonexposed as the reference (rate ratio = 4.3; 95% confidence interval = 1.5-12.7 for the highest exposed subjects; P for trend = 0.007), but the association was attenuated when using the low exposed as the referent group (P for trend = 0.08). Similar patterns for rectal cancer were observed when using intensity-weighted exposure-days. The number of rectal cancer cases among the pendimethalin-exposed was small (n = 19). There was some evidence for an elevated risk for lung cancer, but the excess occurred only in the highest exposure category for lifetime pendimethalin exposure. The trends for lung cancer risk were inconsistent for different exposure metrics. CONCLUSIONS: We did not find a clear association of lifetime pendimethalin exposure either with overall cancer incidence or with specific cancer sites.
Authors: Mustafa Dosemeci; Michael C R Alavanja; Andrew S Rowland; David Mage; Shelia Hoar Zahm; Nathaniel Rothman; Jay H Lubin; Jane A Hoppin; Dale P Sandler; Aaron Blair Journal: Ann Occup Hyg Date: 2002-03
Authors: R E Tarone; M C Alavanja; S H Zahm; J H Lubin; D P Sandler; S B McMaster; N Rothman; A Blair Journal: Am J Ind Med Date: 1997-02 Impact factor: 2.214
Authors: Michael C R Alavanja; Mustafa Dosemeci; Claudine Samanic; Jay Lubin; Charles F Lynch; Charles Knott; Joseph Barker; Jane A Hoppin; Dale P Sandler; Joseph Coble; Kent Thomas; Aaron Blair Journal: Am J Epidemiol Date: 2004-11-01 Impact factor: 4.897
Authors: Esther K Wei; Edward Giovannucci; Kana Wu; Bernard Rosner; Charles S Fuchs; Walter C Willett; Graham A Colditz Journal: Int J Cancer Date: 2004-01-20 Impact factor: 7.396
Authors: Dominik D Alexander; Douglas L Weed; Pamela J Mink; Meghan E Mitchell Journal: Int Arch Occup Environ Health Date: 2011-12-10 Impact factor: 3.015
Authors: A Blair; C J Hines; K W Thomas; M C R Alavanja; L E Beane Freeman; J A Hoppin; F Kamel; C F Lynch; J H Lubin; D T Silverman; E Whelan; S H Zahm; D P Sandler Journal: Am J Ind Med Date: 2015-02 Impact factor: 2.214
Authors: Gabriella Andreotti; Laura E Beane Freeman; Lifang Hou; Joseph Coble; Jennifer Rusiecki; Jane A Hoppin; Debra T Silverman; Michael C R Alavanja Journal: Int J Cancer Date: 2009-05-15 Impact factor: 7.396
Authors: Won Jin Lee; Dale P Sandler; Aaron Blair; Claudine Samanic; Amanda J Cross; Michael C R Alavanja Journal: Int J Cancer Date: 2007-07-15 Impact factor: 7.396
Authors: Sabiha M Ansari; Quaiser Saquib; Sabry M Attia; Eslam M Abdel-Salam; Hend A Alwathnani; Mohammad Faisal; Abdulrahman A Alatar; Abdulaziz A Al-Khedhairy; Javed Musarrat Journal: Histochem Cell Biol Date: 2017-11-18 Impact factor: 4.304